DUROLANE

Durolane is used in the treatment of osteoarthritis and is injected into the knee or hip joint to reduce pain and increase mobility. Sales, marketing and development of Durolane are done via strategic collaboration with Q-Med’s partner, Smith & Nephew, who carry the costs for clinical development, registration work and global commercialization. Q-Med’s revenues for Durolane consist of sales revenues and royalty payments. There are also the remaining one-time payments of up to 60 MUSD which can fall due if certain conditions are met. Of this sum 10 MUSD was paid when the agreement was entered into in 2006. Durolane is today sold in 20 countries and has been used by more than 350,000 patients all over the world. The work of registering Durolane in the American market is ongoing.